



AUG 1 0 1992

GROUP 1800

Atty. Docket No. 8636

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS

David H. Gelfand et al.

SERIAL NO.

07/873,897

GROUP ART: 1808

(on sidened

FILED

April 24, 1992

EXAMINER: D. Naff

DOCKET NO.

8636

TITLE

PURIFIED THERMOSTABLE ENZYME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56, §1.97, AND §1.98

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

The Examiner may find the following references and information, submitted in accordance with the duty of the disclosure under 37 C.F.R. §1.56, §1.97, and §1.98, material in the examination of the above-identified application. The Examiner is requested to make the following information and references of official record in the application.

The present invention provides stabilized thermostable nucleic acid polymerase compositions. Since 1987 and due to the benefits provided by the present application, thermostable nucleic acid polymerases have come into widespread use. Suppliers that formulate their thermostable nucleic acid polymerase with the stabilizers of the present invention have met with great commercial success. These stabilizers, non-ionic polymeric detergents, help maintain polymerase activity in purified preparations of thermostable nucleic acid polymerase during the heating and cooling steps of the PCR nucleic acid amplification process.

The present application is a Rule 62 file wrapper continuation of U.S. Serial No. 07/387,003, filed July 28, 1989, now abandoned.

An Information Disclosure Statement was filed in the parent application, U.S. Serial No. 07/387,003, on May 7, 1990. This Information Disclosure Statement provides publications, patents, and patent applications which all relate to the claimed invention. Copies of the Information

I herby certify that this correspondance is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of patents and Trademarks, Washington, D.C. 20231, on

1

PATENT Atty. Docket No. 8636

Disclosure Statement, and corresponding P.T.O. 1449 form filed in U.S. Serial No. 07/387,003, are attached for Examiner's review, and Applicants request that these documents be made of record in the present continuation application. Because of the availability to Examiner of the '003 file, copies of the references listed on the '003 Information Disclosure Statement are not included. Applicants will readily supply any of these references upon request by Examiner.

Since the Information Disclosure Statement is submitted within three months of the filing date for the above application, no fee is due.

This Information Disclosure Statement under 37 C.F.R. §1.56, §1.97, and §1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under 35 U.S.C. §102 and §103.

Respectfully submitted,

By:

Stacey R. Sias, Ph.D. Agent for Applicants Reg. No. 32,630

July 24, 1992

Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110-1199 (510) 814-2863